|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| Market Cap | 1.55B 1.37B 1.28B 1.17B 2.2B 149B 2.23B 15.52B 6.02B 76.02B 5.81B 5.68B 244B | P/E 2026 * |
14.4x | P/E 2027 * | 12.7x |
|---|---|---|---|---|---|
| Enterprise Value | 1.7B 1.51B 1.41B 1.28B 2.42B 163B 2.44B 17.03B 6.6B 83.39B 6.37B 6.23B 268B | EV / Sales 2026 * |
1.54x | EV / Sales 2027 * | 1.2x |
| Free-Float |
86.75% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Biosante Pharmaceuticals Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Nikhil Lalwani
CEO | Chief Executive Officer | 48 | 08/09/2020 |
Stephen Carey
DFI | Director of Finance/CFO | 55 | 06/05/2016 |
Elizabeth Powell
CMP | Compliance Officer | - | 24/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Haughey
CHM | Chairman | 62 | 24/11/2025 |
Antonio Pera
BRD | Director/Board Member | 68 | 06/08/2020 |
Jeanne A. Thoma
BRD | Director/Board Member | 66 | 06/08/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.21% | -3.43% | +36.07% | +115.04% | 1,019B | |
| -0.77% | -5.60% | +35.72% | +64.63% | 617B | |
| -0.73% | -0.58% | +12.36% | +77.95% | 464B | |
| -2.42% | -3.01% | +61.79% | +41.24% | 356B | |
| +0.56% | -2.08% | +20.67% | +41.06% | 333B | |
| +0.14% | -3.36% | +10.89% | +34.50% | 267B | |
| -0.52% | -4.92% | -6.66% | +8.95% | 244B | |
| -0.68% | -2.79% | +35.30% | +51.84% | 218B | |
| -0.56% | -4.10% | +28.44% | +93.66% | 179B | |
| Average | -0.42% | -3.54% | +26.06% | +58.76% | 410.8B | |
| Weighted average by Cap. | -0.16% | -3.54% | +29.08% | +70.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.1B 981M 916M 835M 1.57B 106B 1.59B 11.08B 4.29B 54.27B 4.15B 4.06B 174B | 1.23B 1.09B 1.02B 930M 1.75B 118B 1.77B 12.34B 4.78B 60.45B 4.62B 4.52B 194B |
| Net income | 114M 101M 94.52M 86.15M 162M 10.96B 164M 1.14B 443M 5.6B 428M 419M 17.98B | 128M 114M 106M 96.87M 183M 12.32B 184M 1.29B 498M 6.3B 481M 471M 20.21B |
| Net Debt | 150M 133M 124M 113M 214M 14.42B 216M 1.51B 583M 7.37B 563M 551M 23.66B | -68.85M -61.17M -57.1M -52.04M -98.15M -6.62B -99.06M -691M -268M -3.38B -259M -253M -10.86B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
